Evidence map›Paper›PMID 34840513›Full record

ArticleYonago acta medica2021

Physical Characteristics of Injection Site Pain After COVID-19 mRNA BNT162b2 Vaccination.

Katsuyuki Tomita, Shinichi Okada, Shuji Sugihara, Tomoyuki Ikeuchi, Hirokazu Touge, Junichi Hasegawa, Akira Yamasaki

Open access · diamondAbstract read
In one paragraph

Article in Yonago acta medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Vaccines · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Katsuyuki TomitaDepartment of Respiratory Medicine, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan.
Shinichi OkadaDepartment of Pediatrics, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan.
Shuji SugiharaDepartment of Radiology, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan.
Tomoyuki IkeuchiDepartment of Respiratory Medicine, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan.
Hirokazu TougeDepartment of Respiratory Medicine, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan.
Junichi HasegawaDepartment of Internal Medicine, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan.
Akira YamasakiDivision of Medical Oncology and Molecular Respirology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan.
National Institute of Technology, Yonago College · JPNational Hospital Organization · JPTottori University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBNT162b2, an mRNA COVID-19 vaccine, was launched in many countries as an intramuscular vaccination for COVID-19 infection. Few studies have assessed the physical indications of pain at the immunization site. This study aimed to characterize pain at the injection site and investigate morphological attributes using ultrasound.

methodsForty-three of 211 healthcare workers who received a second dose of BNT162b2 between February 2021 and March 2021 were enrolled in the study. The mean age of the subjects was 40 years. We evaluated patients' pain at the injection site using the Numerical Rating Pain Scale (NRPS). We also assessed the thickness of the deltoid muscle fascia at the injection site by ultrasound. Bayesian robust correlation was employed to explore the relationship between the pain intensity scores and ultrasound measurements.

resultsAll eligible subjects complained of pain at the injection site. A median pain onset of 8 hours post-vaccination and a median peak intensity score of 4 were reported. Onset of relief occurred after 2 days. Ultrasound images demonstrated a 2.5-fold increase in fascia thickness at the injection site without intramuscular echogenicity change in all subjects. A correlation was established between the NRPS score and the non-injection-to-injection-side ratio of fascia thickness at the injection site (rho = 0.66).

conclusionA sore arm was the most prevalent side effect of BNT162b2 vaccination and could be attributed to temporal fasciitis.

Indexed as

COVID-19 fasciitisintramuscular injectionvaccination

Identifiers

PMID34840513
PMCPMC8612875
OpenAlexW3213223467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.